all report title image
  • Published On : Sep 2020
  • Code : CMI2824
  • Industry : Pharmaceutical
  • Pages : 172
  • Formats :
Ingographics Image

Obesity is defined as excess body fat accumulation. The major factors contributing to obesity throughout the world are diseases and adoption of unhealthy life. Increasing prevalence of obesity in developed and emerging economies of the world is projected to propel the growth of the market during the forecasted period. For instance, according to reports published by the World Federation of Obesity, roughly 27.4 million children in India will be obese by 2030. This rapid increase in childhood obesity in India is expected to increase demand for weight loss and obesity management techniques during the forecast period.

Restraints of the Global Obesity Management Drugs Market

Major factors hampering the growth of the obesity management drugs market during the forecast period constitutes of lack of proper healthcare infrastructure along with improper development and implementation of clinical practice guidelines.

Key features of the study:

  • This report provides in-depth analysis of the global obesity management drugs market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2020–2027), considering 2019, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global obesity management drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include F Hoffmann La Roche Ltd., GlaxoSmithKline plc., Orexigen Therapeutics, Inc., Arena Pharmaceuticals, Inc., VIVUS, Inc., Novo Nordisk A/S, and Eisai Co., Ltd.
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global obesity management drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

  • Global Obesity Management Drugs Market, By Drug Type:
    • Bupropion and Naltrexone
    • Orlistat
    • Lorcaserin
    • Phentermine and Topiramate
    • Liraglutide
  • Global Obesity Management Drugs Market, By Distribution Channel:
    • Hospitals Pharmacies
    • Retail Pharmacies
    • E-commerce
  • Global Obesity Management Drugs Market, By Geography:
    • North America
      • By Drug Type
        • Bupropion and Naltrexone
        • Orlistat
        • Lorcaserin
        • Phentermine and Topiramate
        • Liraglutide
      • By Distribution Channel
        • Hospitals Pharmacies
        • Retail Pharmacies
        • E-commerce
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Drug Type
        • Bupropion and Naltrexone
        • Orlistat
        • Lorcaserin
        • Phentermine and Topiramate
        • Liraglutide
      • By Distribution Channel
        • Hospitals Pharmacies
        • Retail Pharmacies
        • E-commerce
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Type
        • Bupropion and Naltrexone
        • Orlistat
        • Lorcaserin
        • Phentermine and Topiramate
        • Liraglutide
      • By Distribution Channel
        • Hospitals Pharmacies
        • Retail Pharmacies
        • E-commerce
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Drug Type
        • Bupropion and Naltrexone
        • Orlistat
        • Lorcaserin
        • Phentermine and Topiramate
        • Liraglutide
      • By Distribution Channel
        • Hospitals Pharmacies
        • Retail Pharmacies
        • E-commerce
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East:
      • By Drug Type
        • Bupropion and Naltrexone
        • Orlistat
        • Lorcaserin
        • Phentermine and Topiramate
        • Liraglutide
      • By Distribution Channel
        • Hospitals Pharmacies
        • Retail Pharmacies
        • E-commerce
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Type
        • Bupropion and Naltrexone
        • Orlistat
        • Lorcaserin
        • Phentermine and Topiramate
        • Liraglutide
      • By Distribution Channel
        • Hospitals Pharmacies
        • Retail Pharmacies
        • E-commerce
      • By Country/Region:
        • Central Africa
        • South Africa
        • North Africa
  • Company Profiles
    • F Hoffmann La Roche Ltd.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • GlaxoSmithKline plc.
    • Orexigen Therapeutics, Inc.
    • Arena Pharmaceuticals, Inc.
    • VIVUS, Inc.
    • Novo Nordisk A/S
    • Eisai Co., Ltd.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snippet, By Distribution Channel
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Regulatory Scenario
    • PEST Analysis
    • COVID-19 Impact Analysis
  4. Global Obesity Management Drugs Market, By Drug Type, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Bupropion and Naltrexone
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Orlistat
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Lorcaserin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Phentermine and Topiramate
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Liraglutide
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
  5. Global Obesity Management Drugs Market, By Distribution Channel, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Hospitals Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • E-commerce
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Obesity Management Drugs Market, By Regions, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  7. Competitive Landscape
    • Company Profiles
      • F Hoffmann La Roche Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • GlaxoSmithKline plc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Orexigen Therapeutics, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Arena Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • VIVUS, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Novo Nordisk A/S
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Eisai Co., Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 31 market data tables and 22 figures on “Obesity Management Drugs Market – Global forecast to 2027.

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo